Journal
AMERICAN JOURNAL OF PSYCHIATRY
Volume 172, Issue 1, Pages 71-81Publisher
AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2014.14020173
Keywords
-
Categories
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases [R18DK076775]
- AHRQ
- Kaiser Permanente Center for Safety and Effectiveness Research
- Kaiser Permanente Community Benefit Initiative
- NIDA
- NIDDK
- NIH
- NIMH
- Purdue Pharma
- NCCAM
- GenomeDX Biosciences
- Pfizer
- Health Resources and Services Administration
- Lucile Packard Foundation for Children's Health, Maternal and Child Health Bureau
- Centers for Disease Control and Prevention
- Kaiser Permanente Northwest
- Merck
- NCI
- NCMHD
- NHLBI
- NIA
- NICHD
- NINR
- NIOSH
- Veterans Administration
- AstraZeneca
- Bristol-Myers Squibb
- GlaxoSmithKline
- Novartis Pharmaceuticals
- NCRR
Ask authors/readers for more resources
Objectives: The STRIDE study assessed whether a lifestyle intervention, tailored for individuals with serious mental illnesses, reduced weight and diabetes risk. The authors hypothesized that the STRIDE intervention would be more effective than usual care in reducing weight and improving glucose metabolism. Method: The study design was a multisite, parallel two-arm randomized controlled trial in community settings and an integrated health plan. Participants who met inclusion criteria were >= 18 years old, were taking antipsychotic agents for >= 30 days, and had a body mass index >= 27. Exclusions were significant cognitive impairment, pregnancy/breastfeeding, recent psychiatric hospitalization, bariatric surgery, cancer, heart attack, or stroke. The intervention emphasized moderate caloric reduction, the DASH (Dietary Approaches to Stop Hypertension) diet, and physical activity. Blinded staff collected data at baseline, 6 months, and 12 months. Results: Participants (men, N=56; women, N=144; mean age=47.2 years [SD=10.6]) were randomly assigned to usual care (N=96) or a 6-month weekly group intervention plus six monthly maintenance sessions (N=104). A total of 181 participants (90.5%) completed 6-month assessments, and 170 (85%) completed 12-month assessments, without differential attrition. Participants attended 14.5 of 24 sessions over 6 months. Intent-to-treat analyses revealed that intervention participants lost 4.4 kg more than control participants from baseline to 6 months (95% CI=-6.96 kg to -1.78 kg) and 2.6 kg more than control participants from baseline to 12 months (95% CI=-5.14 kg to -0.07 kg). At 12 months, fasting glucose levels in the control group had increased from 106.0 mg/dL to 109.5 mg/dL and decreased in the intervention group from 106.3 mg/dL to 100.4 mg/dL. No serious adverse events were study-related; medical hospitalizations were reduced in the intervention group (6.7%) compared with the control group (18.8%). Conclusions: Individuals taking antipsychotic medications can lose weight and improve fasting glucose levels. Increasing reach of the intervention is an important future step.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available